Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - Essex Bio-Technology/Shanghai Henlius Biotech

Next Previous
Drug Profile

Bevacizumab biosimilar - Essex Bio-Technology/Shanghai Henlius Biotech

Alternative Names: Bevacizumab injection; EB 12 20145P; Hanbeitai; HLX 04; HLX04-O; LONGIVA; rhuMAb-VEGF biosimilar - Shanghai Henlius Biotech

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Henlius Biotech
  • Developer Eurofarma; Shanghai Henlius Biotech
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer
  • Registered Cancer
  • Phase III Wet age-related macular degeneration
  • Phase II Liver cancer
  • No development reported Diabetic retinopathy; Solid tumours

Most Recent Events

  • 09 Apr 2025 Shanghai Henlius Biotech announces intention to submit a New Drug Application (NDA) for Wet age-related macular degeneration in China
  • 09 Apr 2025 Efficacy and safety data from a phase III trial in Wet age-related macular degeneration released by Shanghai Henlius Biotech
  • 19 Feb 2025 Registered for Cancer in Bolivia (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top